hsa-mir-639: Hsa-mir-639 is a microRNA that has been extensively studied in various contexts [PMC7330659]. It has been found to possess putative binding sites for hsa-miR-3664-5p, hsa-miR-4296, and hsa-mir-639 [PMC3378551]. In patients with dilated cardiomyopathy (DCM), hsa-mir-639 was observed to be downregulated compared to patients with DCM and recovered ventricular function, suggesting its potential as a diagnostic and prognostic biomarker [PMC6364251]. Hsa-mir-639 has also been found in promoter GQMs of microRNAs, indicating its involvement in gene regulation [PMC2238908]. Additionally, it was identified as part of a predictive signature for recurrence-free survival (RFS) [PMC9221286]. Hsa-mir-639 is distinctive of microvesicles (MVs) compared to exosomes (EXOs), as it was found to be present in MVs but absent in EXOs [PMC5635803]. In various cancer pathways such as breast, colorectal, pancreatic, gastric, and prostate cancer, hsa-mir-639 has been implicated as a regulator [PMC8956157]. It has also been associated with cell proliferation and cell cycle regulation by targeting CDKN1A in other diseases [PMC9761943]. Furthermore, hsa-mir-639 was found to be downregulated in adolescent and young adult (AYA) patients compared to pediatric patients [PMC9456032]. Dysregulation of hsa-mir-639 has also been observed between adenomatous and carcinoma tissue [PMC5023115]. Overall, these studies highlight the potential role of hsa-mir-639 in various biological processes and diseases [PMC5630327].